Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia. Dumas PY, et al. Among authors: forcade e. Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9. Cancer Med. 2019. PMID: 31287239 Free PMC article.
Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Gaffet M, Wiedemann A, Dalle JH, Bilger K, Forcade E, Robin M, Cornillon J, Labussière-Wallet H, Ceballos P, Bulabois CE, Loschi M, Orvain C, Rubio MT, Neven B, Pagliuca S, Pochon C. Gaffet M, et al. Among authors: forcade e. Br J Haematol. 2023 Jun;201(6):1153-1158. doi: 10.1111/bjh.18744. Epub 2023 Mar 27. Br J Haematol. 2023. PMID: 36974355
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature.
Robin M, Gras L, Koster L, Saccardi R, Finke J, Forcade E, Rovira M, Kobbe G, Reményi P, Apperley J, Smaranda A, Bay JO, Casper J, de Wreede LC, Giebel S, Grillo G, Heras I, Potter V, Tischer J, Trociukas I, Nachbaur D, Drozd-Sokolowska J, Raj K, Gurnari C, Yakoub-Agha I, Onida F, Scheid C, McLornan D. Robin M, et al. Among authors: forcade e. Bone Marrow Transplant. 2023 Aug;58(8):942-945. doi: 10.1038/s41409-023-01991-9. Epub 2023 Apr 25. Bone Marrow Transplant. 2023. PMID: 37185613 No abstract available.
Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, Ionescu I, Gluckman E, Milpied N, Rocha V. Dumas PY, et al. Among authors: forcade e. Bone Marrow Transplant. 2013 Feb;48(2):253-6. doi: 10.1038/bmt.2012.117. Epub 2012 Jul 9. Bone Marrow Transplant. 2013. PMID: 22773124
Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
Gros FX, Cazaubiel T, Forcade E, Lechevalier N, Leguay T, Servant V, Tabrizi R, Clement L, Dumas PY, Bidet A, Pigneux A, Vigouroux S, Milpied N. Gros FX, et al. Among authors: forcade e. Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5. Bone Marrow Transplant. 2017. PMID: 28581465 No abstract available.
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.
Dumas PY, Bertoli S, Bérard E, Médiavilla C, Yon E, Tavitian S, Leguay T, Huguet F, Forcade E, Milpied N, Sarry A, Sauvezie M, Bories P, Pigneux A, Récher C. Dumas PY, et al. Among authors: forcade e. Oncotarget. 2017 Mar 7;8(45):79126-79136. doi: 10.18632/oncotarget.15988. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108292 Free PMC article.
HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.
Ducreux S, Dubois V, Amokrane K, Yakoub-Agha I, Labalette M, Michallet M, Rubio MT, Kennel A, Forcade E, Lafarge X, Bulabois CE, Masson D, Daguindau E, Devys A, Moalic V, Quelvennec E, Boudifa A, Picard C, Van Endert P, de Matteis M, Delbos F, Filloux M, Pedron B, Renac V, Hau F, Bonneau J, Parissiadis A, Fort M, Dormoy A, Maillard N, Jollet I, Chevallier P, Cesbron A, Bay JO, Quainon F, Garnier F, Socié G, Loiseau P, Porcher R, Peffault de Latour R; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI). Ducreux S, et al. Among authors: forcade e. Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. Online ahead of print. Am J Hematol. 2018. PMID: 29726580 Free article.
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
Calmettes C, Gabriel F, Blanchard E, Servant V, Bouchet S, Kabore N, Forcade E, Leroyer C, Bidet A, Latrabe V, Leguay T, Vigouroux S, Tabrizi R, Breilh D, Accoceberry I, de Lara MT, Pigneux A, Milpied N, Dumas PY. Calmettes C, et al. Among authors: forcade e. Oncotarget. 2018 Jun 1;9(42):26724-26736. doi: 10.18632/oncotarget.25477. eCollection 2018 Jun 1. Oncotarget. 2018. PMID: 29928481 Free PMC article.
Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.
Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, Huynh A, Saccardi R, Martino M, Schaap M, Wu D, Mohty M, Nagler A. Shouval R, et al. Among authors: forcade e. Cancer. 2019 Oct 15;125(20):3566-3573. doi: 10.1002/cncr.32344. Epub 2019 Jun 21. Cancer. 2019. PMID: 31225904 Free article.
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.
Schmaelter AK, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Ganser A, Beelen D, Labussière-Wallet H, Passweg J, Savani BN, Schmid C, Nagler A, Mohty M. Schmaelter AK, et al. Among authors: forcade e. Blood Cancer J. 2020 Mar 3;10(3):26. doi: 10.1038/s41408-020-0296-3. Blood Cancer J. 2020. PMID: 32127519 Free PMC article.
150 results